Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma

A technology of osteosarcoma and tinib pharmacy, which is applied in the field of medicine to achieve the effect of enhancing the killing effect

Active Publication Date: 2018-05-01
CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF4 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report about the application of anlotinib in osteosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma
  • Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma
  • Application of novel tyrosine kinase inhibitor-anlotinib in osteosarcoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1. Materials and Methods

[0027] 1.1 Materials Human osteosarcoma cell lines 143B, U2OS, MG63 and SJSA were purchased from the American Type Culture Collection (ATCC). Anlotinib (a new type of tyrosine kinase inhibitor) is derived from Chia Tai Tianqing Pharmaceutical Group Co., Ltd., dissolved in dimethyl sulfoxide, configured as a working mother solution of 16mMol / L, and placed in a -20°C Store in the refrigerator for later use, and adjust to the required concentration with DMEM serum culture medium before use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of anlotinib and belongs to the technical field of medicine, namely effects of anlotinib in inhibition of growth and metastasis of osteosarcoma. The application disclosed by the invention has the advantages that the effect of the anlotinib for inhibiting growth and metastasis of osteosarcoma is discovered for the first time. The anlotinib is capable of obviously inhibiting the growth of osteosarcoma cell lines 143B, U2OS, MG63 and SJSA, inducing cycle arrest of the osteosarcoma and inhibiting migration and invasiveness of the osteosarcoma cell lines.The anlotinib is first discovered to be capable of enhancing a killing effect of chemotherapeutic cis-platinum on osteosarcoma cells.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to the application of anlotinib in osteosarcoma. Background technique [0002] Anlotinib is a small-molecule multi-target tyrosine kinase inhibitor developed by my country with independent intellectual property rights. Its compound patent publication number is WO2008 / 112407. It obtained clinical approval in 2011 and entered phase I clinical trials Completed in 2013, clinical trials of Anlotinib for various cancers are underway, including non-small cell lung cancer, soft tissue sarcoma, gastric cancer, colorectal cancer, medullary thyroid cancer, differentiated thyroid cancer, esophageal squamous cell carcinoma, etc. [0003] International Publication No.: WO2008 / 112407 and Chinese Patent No.: ZL200880007358.X patent documents disclose the inhibitory activity of anlotinib on colon cancer, non-small cell lung cancer, liver cancer and breast cancer. But there is no report about the a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4709A61P35/00
CPCA61K31/4709A61K33/243A61P35/00A61P35/04A61K2300/00
Inventor 华莹奇王刚阳蔡郑东王卓莹张涛汪红胜孙梦熊
Owner CHIA TAI TIANQING PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap